NRIX stock forecast, quote, news & analysis
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases... Show more
Nurix Therapeutics (NRIX) Stock Analysis: Roche Partnership Reshapes the Targeted Protein Degradation Landscape
Key Takeaways
- Nurix Therapeutics shares traded near $23.73 in late July 2026, consolidating after a transformative quarter driven by the landmark Roche collaboration for BTK degrader bexobrutideg.
- The global co-development and co-commercialization agreement with Roche includes a $700 million upfront payment and up to $2.3 billion in total potential milestone payments.
- Updated Phase 1a/1b clinical data presented at EHA 2026 demonstrated compelling efficacy, with an 83% overall response rate and median progression-free survival of 22.1 months in relapsed/refractory CLL.
- Nurix reported a wider Q2 fiscal 2026 net loss of $89.5 million as R&D spending accelerated, while pro-forma cash of approximately $1.14 billion provides an extended runway.
- Expansion beyond oncology into immunology and neurology — with planned Phase 2 trials in multiple sclerosis and chronic spontaneous urticaria — broadens the company's addressable market.
Current Market Snapshot
Nurix Therapeutics (NRIX) has been one of the more closely watched names in the mid-cap biotechnology sector following a series of high-impact announcements in mid-2026. After trading as low as $14.64 in early June, shares surged on the Roche collaboration announcement and subsequent clinical data presentations, reaching a 52-week high of $25.08 in July before settling into a consolidation range around $23–$24. Over the most recent 30-day period, the stock has traded relatively sideways, reflecting a market that has largely priced in the Roche deal's near-term implications and is now awaiting execution milestones. The broader biotech sector has seen mixed sentiment amid macroeconomic uncertainty, though targeted protein degradation remains a high-conviction therapeutic modality among institutional investors.
Nurix Therapeutics (NRIX) Business Overview and Competitive Position
Nurix Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation — an emerging field that aims to eliminate disease-causing proteins rather than merely inhibiting them. The company's lead asset, bexobrutideg (NX-5948), is an orally bioavailable, brain-penetrant BTK degrader designed to overcome resistance mechanisms that limit conventional BTK inhibitors. Nurix's AI-integrated DEL-AI discovery platform and deep expertise in E3 ligase biology underpin a pipeline that spans oncology, immunology, and neurology. Beyond the Roche-partnered bexobrutideg program, Nurix maintains collaborations with GILD (Gilead Sciences), SNY (Sanofi), and PFE (Pfizer), with retained options for U.S. co-development and profit sharing across multiple programs. The company's internal pipeline also includes NX-1607, an oral CBL-B inhibitor, and several preclinical degrader and degrader antibody conjugate (DAC) candidates.
Recent Developments Driving NRIX
The single most consequential event for Nurix in 2026 has been the global collaboration agreement with RHHBY (Roche), announced on June 8 and formally closed on July 21 following HSR antitrust clearance. Under the terms, Nurix receives a $700 million upfront cash payment and is eligible for up to $2.3 billion in total milestone payments. Development costs are split 40/60 (Nurix/Roche), and U.S. profits and losses are shared equally. This deal effectively transforms Nurix's balance sheet, bringing pro-forma cash to approximately $1.14 billion.
At the European Hematology Association (EHA) 2026 meeting, Nurix presented updated clinical data from the NX-5948-301 Phase 1a/1b study that reinforced bexobrutideg's best-in-class potential. Phase 1a results showed an 83% objective response rate and median progression-free survival of 22.1 months. Phase 1b cohorts demonstrated response rates of 92.9% in BTK inhibitor-experienced, BCL2 inhibitor-naïve patients and 84.2% in BTK inhibitor-naïve patients. Enrollment continues in the pivotal Phase 2 DAYBreak CLL-201 trial, and the randomized Phase 3 DAYBreak CLL-306 confirmatory study is expected to dose its first patient in mid-2026.
On the financial front, Nurix reported Q2 fiscal 2026 revenue of $9.0 million, down from $44.1 million a year earlier due to the absence of prior-year Sanofi license extension revenue. R&D expenses rose to $87.7 million as the company accelerated clinical development. The net loss widened to $89.5 million, or $0.81 per share. The company also presented preclinical data at the 2026 AACR Annual Meeting and translational data supporting bexobrutideg's potential in chronic spontaneous urticaria at the Society for Investigative Dermatology Annual Meeting.
Trending AI Robots
Investors seeking to navigate the fast-moving biotechnology sector may benefit from algorithmic trading strategies designed to identify opportunities across thousands of equities. Tickeron's Trending AI Robots page showcases a curated selection of top-performing AI-powered trading bots from a broader ecosystem of hundreds of automated strategies. These bots employ diverse methodologies — ranging from technical pattern recognition to fundamental and sentiment-driven models — across varying time horizons and risk profiles. Each bot's historical performance metrics, strategy logic, and recent trade history are displayed transparently, enabling traders to evaluate alignment with their own investment approach. The Trending AI Robots section is regularly updated to highlight the most relevant and consistently performing strategies available on the platform.
2026 Outlook and What Investors Should Watch
Looking ahead, several catalysts could shape Nurix's trajectory through the remainder of 2026 and into 2027. The initiation of the Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg against LLY (Eli Lilly's) pirtobrutinib represents a critical value-inflection point, as it will be the first randomized data readout for the degrader. Additionally, the planned initiation of Phase 2 studies in multiple sclerosis and chronic spontaneous urticaria opens entirely new therapeutic markets beyond hematologic oncology. Investors should monitor enrollment progress across the pivotal CLL program, any additional data presentations at major medical conferences, and the company's cash burn rate as it scales its co-development obligations under the Roche partnership. Regulatory clarity around accelerated approval pathways for targeted protein degraders, broader biotech sector sentiment, and macroeconomic factors influencing risk appetite in pre-revenue biotechnology companies also warrant close attention.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for NRIX shows an upward move is likely
NRIX's Aroon Indicator triggered a bullish signal on July 20, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 176 similar instances where the Aroon Indicator showed a similar pattern. In of the 176 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 30, 2026. You may want to consider a long position or call options on NRIX as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for NRIX moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for NRIX turned negative on July 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NRIX broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.477) is normal, around the industry mean (20.354). P/E Ratio (0.000) is within average values for comparable stocks, (25.057). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.600). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (68.493) is also within normal values, averaging (411.278).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders
Industry Biotechnology